Actually,
3. Despite using substandard industry stastistical analyses protocols, IMU's most advanced product HER-Vaxx failed to show a significant benefit over standard of care chemotherapy for progression free survival in their phase II trial.
Here is a link to my explannation of the above point.
You and many others seem to have missed the only thing that really matters for a biotechnology company; data. I have repeatedly tried to help highlight this for people, but no one seems to care.
Industry news, page-237
-
- There are more pages in this discussion • 1,968 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.050(2.98%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $48.25K | 29.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 100 | 1 |
View Market Depth
| Last trade - 11.51am 04/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |